Evidence map›Paper›PMID 35903711›Full record

ArticleFrontiers in oncology2022

Evaluation of Pharmacokinetics of Boronophenylalanine and Its Uptakes in Gastric Cancer.

Futian Tang, Yujie Wei, Shining Zhang, Jianrong Wang, Wenjiao Gu, Fenxia Tang, Xiaohuan Peng, Yucai Wei, Jiangyan Liu, Weiqiang Chen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Uptakes of boronophenylalanine in theIBRO neuroscience reports · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Futian TangKey Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China.
Yujie WeiKey Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China.
Shining ZhangKey Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China.
Jianrong WangKey Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China.
Wenjiao GuKey Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China.
Fenxia TangKey Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China.
Xiaohuan PengKey Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China.
Yucai WeiKey Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China.
Jiangyan LiuNuclear Medicine Department, Lanzhou University Second Hospital, Lanzhou, China.
Weiqiang ChenKey Laboratory of Heavy Ion Radiation Biology and Medicine, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.
Shixu ZhangSchool of Nuclear Science and Technology, Lanzhou University, Lanzhou, China.
Long GuSchool of Nuclear Science and Technology, Lanzhou University, Lanzhou, China.
Yumin LiKey Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China.
Lanzhou University Second Hospital · CNLanzhou University · CNInstitute of Modern Physics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Boron neutron capture therapy (BNCT), a cellular-level particle radiation therapy, combines boron compounds selectively delivered to tumor tissue with neutron irradiation. Boronophenylalanine (BPA) is a boron compound widely used in malignant melanoma, malignant brain tumors, and recurrent head and neck cancer. However, neither basic nor clinical research was reported for the treatment of gastric cancer using BPA. Selective distribution of boron in tumors rather than that in blood or normal tissue prior to neutron irradiation is required for the successful treatment of BNCT. This study evaluated the pharmacokinetics and safety of

Indexed as

boron neutron capture therapyboronophenylalaninegastric cancerMKN45 cellspharmacokineticssafety

Identifiers

PMID35903711
PMCPMC9314552
OpenAlexW4285023230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.